vorozole has been researched along with Breast Neoplasms in 37 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 21 (56.76) | 18.2507 |
2000's | 10 (27.03) | 29.6817 |
2010's | 5 (13.51) | 24.3611 |
2020's | 1 (2.70) | 2.80 |
Authors | Studies |
---|---|
Muftuoglu, Y; Mustata, G | 1 |
Potter, BV; Thomas, MP | 1 |
Airola, K; Biegon, A; Bonilla, P; Cohen, J; Dhawan, J; Franceschi, D; Pareto, D; Shroyer, KR; Tahmi, M | 1 |
Alonso, A; Laenen, A | 1 |
Jiao, J; Liao, Q; Xiang, H | 1 |
A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
Mokbel, K | 1 |
Clemons, MJ; Freedman, OC; Verma, S | 1 |
Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E | 1 |
Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP | 1 |
De Coster, R; Snoeck, E; Wouters, W | 1 |
Blankenstein, RA; de Jong, PC; Donker, TH; Maitimu-Smeele, I; Nortier, HW; Slee, PH; Thijssen, JH; van de Ven, J | 1 |
Dowsett, M | 2 |
Durgam, VR; Tekmal, RR | 1 |
Amoroso, D; Boccardo, F; Brema, F; Cortesi, E; Farris, A; Guida, G; Iacobelli, S; Irtelli, L; Langenaeken, C; Mesiti, M; Mustacchi, G; Nardini, P; Pacini, P | 1 |
Buzdar, AU; Roseman, BJ; Singletary, SE | 1 |
Beex, LV; Houston, SJ; Klijn, J; Langenaeken, C; Nooij, M; Paridaens, R; Piccart, MJ; Roy, JA; Tomiak, E; Van Glabbeke, M; Van Vreckem, A; Vinholes, J | 1 |
Harvey, HA | 1 |
Beex, LV; Bonfrer, JM; Bruning, PF; Bruynseels, J; Klijn, JG; Nooij, M; Paridaens, R; Piccart, MJ | 1 |
Huang, ML; Langenaecken, C; Piotrovsky, VK; Van Peer, A | 1 |
Goss, PE | 1 |
Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA | 1 |
Bruynseels, J; De Coster, R; Goss, PE; Langenaeken, C; Walde, D | 1 |
Hamilton, A; Piccart, M | 1 |
Goss, PE; Schwartz, LH; Tannock, IF; Winer, EP | 1 |
Blijham, GH; de Jong, PC | 1 |
Coombes, RC; Doody, D; Dowsett, M; English, J; Howes, A; Miall, S | 1 |
Bonneterre, J; Feutrie, ML | 1 |
Harvey, HA; Santen, RJ | 1 |
Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N | 1 |
Kerbrat, P; Lefeuvre, C | 1 |
Buzdar, A; Howell, A | 1 |
Boeddinghaus, I; Dixon, M; Dowsett, M; Ebbs, S; Gui, G; Harper-Wynne, C; Hills, M; Sacks, N; Salter, J; Smith, I | 1 |
A'Hern, R; Doody, D; Dowsett, M; Harper-Wynne, CL; Hills, MJ; Howes, A; Iqbal, J; Laidlaw, IJ; Lowe, FM; MacNeill, FA; Miall, S; Nasiri, N; Rayter, Z; Sacks, NP; Salter, J; Sauven, P; Shenton, K | 1 |
Bijnens, L; Michiels, B; Molenberghs, G; Thijs, H; Vangeneugden, T | 1 |
17 review(s) available for vorozole and Breast Neoplasms
Article | Year |
---|---|
Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chromones; Coumarins; Female; Flavonoids; Humans; Letrozole; Nitriles; Receptors, Estrogen; Sulfonamides; Triazoles | 2010 |
The evolving role of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Humans; Letrozole; Nitriles; Triazoles | 2002 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Probability; Prognosis; Remission Induction; Risk Assessment; Survival Analysis; Triazoles | 2005 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2006 |
Vorozole, a specific non-steroidal aromatase inhibitor.
Topics: Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Hormones; Humans; In Vitro Techniques; Male; Mammary Neoplasms, Experimental; Triazoles | 1994 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 1998 |
Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Enzyme Inhibitors; Humans; Neoplasms, Hormone-Dependent; Randomized Controlled Trials as Topic; Triazoles | 1998 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estrogen Antagonists; Estrone; Female; Humans; Letrozole; Nitriles; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting | 2001 |
8 trial(s) available for vorozole and Breast Neoplasms
Article | Year |
---|---|
Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
Topics: Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Middle Aged; Triazoles | 1997 |
Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrone; Female; Humans; Middle Aged; Postmenopause; Triazoles | 1997 |
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EOR
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Hot Flashes; Humans; Middle Aged; Nausea; Tamoxifen; Triazoles | 1998 |
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Hormones; Humans; Middle Aged; Postmenopause; Statistics as Topic; Treatment Outcome; Triazoles | 1998 |
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 1995 |
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Triazoles | 1999 |
Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Topics: Adult; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Goserelin; Humans; Middle Aged; Ovary; Postmenopause; Premenopause; Triazoles | 1999 |
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Enzyme Inhibitors; Female; Follicle Stimulating Hormone; Humans; Ki-67 Antigen; Luteinizing Hormone; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2002 |
12 other study(ies) available for vorozole and Breast Neoplasms
Article | Year |
---|---|
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Simulation; Drug Design; Female; Humans; Models, Chemical; Models, Molecular; Structure-Activity Relationship | 2010 |
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosis; Estrone; Female; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Steryl-Sulfatase; Sulfonic Acids; Tubulin Modulators | 2015 |
Initial Studies with
Topics: Aged; Aromatase; Breast Neoplasms; Carbon Radioisotopes; Female; Humans; Immunohistochemistry; Middle Aged; Positron-Emission Tomography; Triazoles | 2020 |
The Functional Living Index-Cancer: estimating its reliability based on clinical trial data.
Topics: Aged; Antineoplastic Agents; Belgium; Breast Neoplasms; Discriminant Analysis; Female; Humans; Longitudinal Studies; Megestrol Acetate; Middle Aged; Patient Participation; Psychometrics; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Triazoles | 2010 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Clinical development plan: (+)-vorozole.
Topics: Animals; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Enzyme Inhibitors; Estradiol; Female; Humans; Male; Neoplasms, Experimental; Rats; Research Design; Triazoles | 1996 |
Aromatase inhibitors come of age.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Nitriles; Triazoles | 1997 |
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Fadrozole; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Postmenopause; Triazoles; Tumor Cells, Cultured | 1997 |
Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Height; Body Weight; Breast Neoplasms; Female; Humans; Male; Middle Aged; Population; Regression Analysis; Sex Factors; Triazoles | 1998 |
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Disease Progression; Enzyme Inhibitors; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Humans; Middle Aged; Tamoxifen; Time Factors; Treatment Failure; Treatment Outcome; Triazoles | 1999 |
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplification; Humans; Immunohistochemistry; Ki-67 Antigen; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Selection models and pattern-mixture models to analyse longitudinal quality of life data subject to drop-out.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Female; Humans; Longitudinal Studies; Models, Statistical; Neoplasms, Hormone-Dependent; Patient Dropouts; Quality of Life; Triazoles | 2002 |